PolarityTE — Q3 2020 Earnings Presentation
10 slides from PolarityTE's earnings presentation, Nov 9, 2020
Slide 1: Calendar Third Quarter 2020 Financial Results
@ Skinie Calendar Third Quarter 2020 Financial Results November 9, 2020
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and projections. PolarityTE, Inc., (the "Company") makes no express or implied representation or warrant as to the completeness of this information or, in the case of projections, as to their attainability or the accura
Slide 3: Opening Remarks
@ SkiniE Opening Remarks David Seaburg, Chief Executive Officer
Slide 4: Progress Update
Progress Update BLA Preparation * Submitted pre-IND briefing materials to FDA in August * Received FDA feedback in October * Actively developing plan towards submitting IND with multiple indications Streamlined Operations and Capital Efficiency * Q3:20 operational cash burn: 43% lower vs Q3:19 * Q3:
Slide 5: Q3:20 Revenue
Q3:20 Revenue * Total Revenues: ~$3.34 million; up 47% QoQ * SkinTE Revenue: ~$1.16 million; up 22% QoQ * Contract Services Revenue: ~$2.18 million; up 65% QoQ * Includes ~$1.75 million from COVID-19 test processing = Inc, All Rights Re
Slide 6: Regulatory Update
@ SkiniE Regulatory Update Richard Hague, President & COO
Slide 7: Financials
@ SkiniE Financials Jake Patterson, Interim CFO 2020 PolarityTE, inc. All Ric
Slide 8: Financials
Financials USS ‘000 (except per shar: ee al 1Q 2020 (Q2019 |3Q2019 ures) Total Revenues Products Services R&D G&A S&M Cash flow used in Operations Cash Investment into PPE Cash, Cash Equivalents and ST Investments 3,337 1,156 2,181 (2,698) (6,264) (1,606) (6,757) (55) 23,186 2,266 944 428 1,322 505
Slide 9: Questions
@ SkiniE Questions David Seaburg, CEO Richard Hague, President & COO Jake Patterson, Interim CFO Nikolai Sopko, MD, PhD, Chief Scientific Officer
Slide 10: About SkinTE™
About SkinTE™ SkinTE is a human cellular and tissue-based product derived from a patient's own skin (autologous) intended for the repair, reconstruction, replacement, or supplementation of skin tissue. Aseptic surgical procedures and handling during skin harvest, wound preparation, and SkinTE deploy